Think it's time for a booster? Moderna says its newest COVID vaccine is showing signs of a stronger immune response against the virus than the current shot being offered and a longer shelf-life.
Moderna Inc. announced Tuesday that its next-generation COVID vaccine produced better immune results in a late-stage trial than its previous vaccines, and will be a key part of its combination ...
News that the Biden administration is planning to push for Americans to get the updated COVID vaccines this fall caused several vaccine manufacturers' stock prices to rise Monday. Moderna CEO ...
Shares of Moderna ... vaccine data is interesting. In his words, says the data suggests the vaccine could potentially work in industries outside of melanoma. He has a buy rating, price target ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. US biotech Moderna has put plans to build a vaccine plant in Kenya on hold, in a sign that moves to invest ...
Jefferies' revised price target reflects the potential of these upcoming products and milestones for Moderna, as the company continues to expand its vaccine portfolio and explore new therapeutic ...
It also had plans to start filling doses of its COVID vaccine in the continent as early as 2023. However, Moderna has not received any vaccine orders for Africa since 2022 amid waning demand ...
It comes after Pfizer and Moderna, the two key suppliers of Covid vaccines ... with the high price of Boots’ service reflective of the higher cost set by vaccine manufacturers.
"Most of the cases that we're seeing reported are either unvaccinated or under-vaccinated, meaning they either never received a vaccine ... aims to curb this increase by targeting vaccination ...
(Reuters) -Moderna said on Thursday it had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for COVID-19 vaccines. The move is in ...